Status:
UNKNOWN
Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis
Lead Sponsor:
Assiut University
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18-55 years
Brief Summary
Investigators aimed at investigating the prediction ability of faecal calprotectin to predict mucosal healing and histological remission in ulcerative colitis patients receiving biological therapy Inv...
Detailed Description
Ulcerative colitis (UC) is a chronic relapsing disease that involves the colorectal mucosa. Over the years, the therapeutic target has been upgraded from the resolution of symptoms to deep remission t...
Eligibility Criteria
Inclusion
- 24 patients (males and females at the age between 18 and 55 years) of ulcerative colitis indicated to biological therapy
Exclusion
- \- Ulcerative colitis pregnant women
- Patient receiving biological therapy for extra intestinal manifestation
- Patients on corticosteroids more than 20 mg as it affects leucocytic count
- Patients under the age of 18 years
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04818788
Start Date
April 1 2021
End Date
June 1 2022
Last Update
March 29 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.